- Home
- NXTC vs NCRA Comparison
NXTC vs NCRA Comparison
Compare NXTC & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- NCRA
- Stock Information
- Founded
- NXTC 2015
- NCRA 2002
- Country
- NXTC United States
- NCRA Taiwan
- Employees
- NXTC N/A
- NCRA N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- NCRA Farming/Seeds/Milling
- Sector
- NXTC Health Care
- NCRA Consumer Staples
- Exchange
- NXTC Nasdaq
- NCRA Nasdaq
- Market Cap
- NXTC 13.0M
- NCRA 15.1M
- IPO Year
- NXTC 2019
- NCRA N/A
- Fundamental
- Price
- NXTC $5.76
- NCRA $1.55
- Analyst Decision
- NXTC Strong Buy
- NCRA
- Analyst Count
- NXTC 2
- NCRA 0
- Target Price
- NXTC $25.50
- NCRA N/A
- AVG Volume (30 Days)
- NXTC 16.7K
- NCRA 18.6K
- Earning Date
- NXTC 11-06-2025
- NCRA 11-13-2025
- Dividend Yield
- NXTC N/A
- NCRA N/A
- EPS Growth
- NXTC N/A
- NCRA N/A
- EPS
- NXTC N/A
- NCRA N/A
- Revenue
- NXTC N/A
- NCRA $13,865,984.00
- Revenue This Year
- NXTC N/A
- NCRA N/A
- Revenue Next Year
- NXTC N/A
- NCRA N/A
- P/E Ratio
- NXTC N/A
- NCRA N/A
- Revenue Growth
- NXTC N/A
- NCRA N/A
- 52 Week Low
- NXTC $2.69
- NCRA $0.70
- 52 Week High
- NXTC $19.20
- NCRA $2.09
- Technical
- Relative Strength Index (RSI)
- NXTC 66.21
- NCRA 51.92
- Support Level
- NXTC $5.19
- NCRA $1.43
- Resistance Level
- NXTC $5.15
- NCRA $1.60
- Average True Range (ATR)
- NXTC 0.27
- NCRA 0.10
- MACD
- NXTC 0.08
- NCRA -0.01
- Stochastic Oscillator
- NXTC 89.05
- NCRA 75.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.